Previously reported that H2AFY was highly expressed in hepatocellular carcinoma, triple negative breast cancer, colon cancer, lymphoma and melanoma and promoted tumor proliferation [30–34]. This evidence concerns the gene MACROH2A1 and hepatocellular carcinoma.